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Abstract
Background: Pre-exposure prophylaxis (PrEP) is not widely available in China. Previous studies reported low awareness
and inconclusive findings on the acceptability of PrEP among Chinese men who have sex with men (MSM).
Methods: We conducted a secondary analysis of an online national survey comparing preferences for oral and long-
acting injectable PrEP among MSM and identifying correlates of preferences. The study did not collect detailed
information about partner types that may influence negotiated safety and PrEP uptake.
Results: Nine-hundred and seventy-nine men from the larger sample of 1045 men responded to the PrEP survey
questions. Most men (81.9%) had never heard of PrEP, but reported interest in using PrEP. More participants chose
injectable PrEP (36.3%) as their preferred formulation than oral PrEP (24.6%). Men who had at least two HIV tests
(adjusted OR = 1.36, 95%CI 1.04, 1.78) more commonly preferred injectable PrEP.
Conclusion: Our findings may help inform PrEP messaging in areas where PrEP has yet to be scaled up.
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Background
Pre-exposure prophylaxis (PrEP), one of the most effective
biological tools to prevent HIV acquisition, has been
recommended by the World Health Organization (WHO)
for individuals with increased risk of HIV infection, includ-
ing some men who have sex with men (MSM) [1]. Several
trials have demonstrated the effectiveness of PrEP among
high-risk MSM [2, 3]. PrEP uptake has increased in some
countries over the past several years, but rates are still
modest in most countries [4]. Expanding PrEP uptake in
countries could avert many HIV infections. For example,
in China, a modeling study indicated that a PrEP coverage
of 50% in high-risk MSM could prevent 170,000 to 320,
000 of new HIV infections over the next two decades [5].
However, PrEP is not yet approved for clinical use in
China.
PrEP uptake barriers among MSM include low aware-
ness, high cost, limited support from partners, low per-
ceived HIV risk, limited access, and potential problems
with adherence [6–12]. In addition, cultural beliefs about
health, HIV stigma, homophobia, and limited health
insurance coverage for PrEP are further barriers to oral
PrEP uptake [13]. To overcome some of these barriers,
alternative formulations like long-acting injectables have
shown promise in several clinical trials [14, 15]. Long-
acting injectable PrEP could potentially simplify HIV
prevention services, reduce HIV stigma associated with
pill taking, and improve HIV prevention services [16]. A
national study in the US found that among gay and bi-
sexual men who were willing to use PrEP, men preferred
long-acting injectable PrEP compared to oral forms [17].
However, less is known about preferences for inject-
able PrEP in China and other low- and middle-income
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countries [18]. Some studies suggest that MSM in China
have low awareness of PrEP (11.2–33.5%), but high will-
ingness (54.0–67.8%) to potentially use daily PrEP [8, 16,
19]. Chinese MSM sometimes leave the country in order
to purchase PrEP [20]. Conversely, studies in Shanghai
and Hong Kong reported low willingness and low actual
uptake of oral PrEP [18, 19]. The Shanghai study also
found poor adherence among those who initiated PrEP
[18]. More information about PrEP preferences among
MSM would be useful for the introduction and scale-up
of PrEP in China and other locations where PrEP is not
widely available. The purpose of this study was to com-
pare preferences for oral and long-acting injectable PrEP
among MSM and identify correlates of preferences.
Methods
Participants and procedures
This is a secondary analysis of data collected from a cross-
sectional online national study on HIV testing preferences
among Chinese MSM [21]. Participants were recruited
from January 8 to January 312,017 through banner adver-
tisements on web- and mobile app-based platforms on
Blued, a large gay Chinese social media platform. Eligible
participants completed an online survey. Eligibility criteria
included the following: 1) born biologically male; 2) older
than age 16 years; 3) had anal or oral sex with another
man; 4) not diagnosed with HIV. In order to address some
of the shortcomings of online sampling, we assigned sam-
ple quotas for each of the following subgroups: annual in-
come level above and below 5500 USD, educational level
above and below high school, and have and have not
disclosed MSM behaviors to a medical provider. Detailed
recruitment and sampling strategies can be found in a pre-
vious paper [21]. Participants received $7.50 USD mobile
data credits as compensation for their time to complete
the 400-item survey, which took approximately 30min to
finish. This analysis only included men who responded to
at least one survey question on PrEP .
Measures
Socio-demographics
Socio-demographic characteristics were extracted from the
dataset including age (continuous), gender identity (male,
female, transgender, or unsure/other), sexual orientation
(gay, bisexual, or other), educational level (high school or
below versus above high school), annual income (USD
5500 or below versus above USD 5500), and marital status
(never married versus ever married). Disclosure of one’s
sexual orientation to medical provider was also extracted .
Factors related to sexual risk behavior and HIV testing
behavior
Items assessing sexual risk behaviors included seeking sex-
ual partners online in the last 12months (yes/no), number
of male sexual partners in the last 3 months (individuals
who have more than one male partner were classified as
having multiple male sexual partners), condomless sex in
the last 3 months (yes/no), and anal sex role (insertive, re-
ceptive, or both). We also asked participants whether they
had tested for HIV and the number of HIV tests in the
past year. Individuals who had more than one test were
classified as have multiple HIV tests in the past year.
Community engagement in sexual health
In this study, community engagement in sexual health was
defined as awareness, participation, and advocacy for sex-
ual health in the community. Community engagement
was measured by a six-item scale validated among Chinese
MSM [22]. The scale included the following items: dis-
cussed HIV/STI testing or sexual health online, aware of
any MSM sexual health events, encouraged others to get
HIV/STI tested, accompanied others to a HIV/STI testing
facility, helped organize a MSM sexual health campaign,
and volunteered to help provide MSM sexual health ser-
vices [22]. These community engagement items were cate-
gorized into none, minimal, moderate, and substantial
engagement according to previous studies [22].
PrEP acceptability and formulation preferences
Interest in using PrEP and preferences regarding PrEP
formulation were adapted from a study in Vietnam [23]
which included three formulations: oral PrEP, long-
acting injectable PrEP, and rectal microbicides.
Before completing the survey, participants were pro-
vided with a brief introduction to PrEP (Additional file 1:
Table S1). PrEP was described an evidence-based ap-
proach to prevent HIV infection among people at high
risk of infection. Oral PrEP was described as a daily pill.
The effectiveness of oral PrEP was given as reducing 92%
of the risk of HIV infection when taken consistently.
Long-acting injectable PrEP was described as an injection
or shot given every 3months and the effectiveness was de-
scribed as unclear. Rectal microbicide was described as a
gel (like a lubricant) inserted into the rectum before sex
and the effectiveness was described as unclear. In this
study, we focus on the correlates with interests and prefer-
ences on oral and long-acting injectable PrEP.
Participants were asked whether they had heard about
PrEP before this survey. Participants were then asked how
interested they would be in taking each PrEP formulation if
it were made available in China. Their answers were
recoded as interested (very interested, somewhat interested,
interested) and not interested (neutral, somewhat uninter-
ested, very uninterested, not sure) in using PrEP. PreP for-
mulation preferences were asked as follows: “Please rank
your preferred PrEP formulation (from the most to the least
preferred)”. Participants who had no interest in PrEP were
able to skip these questions. Participants who ranked
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injectable PrEP as their most preferred formulation were
defined as preference for injectable PrEP.
Statistical analysis
The sample for this analysis included 979 MSM. The sam-
ple excluded men who did not answer PrEP questions
(n = 66). Descriptive analyses were used to summarize
socio-demographic characteristics and sexual behaviors of
the sample. Logistic regression models were used to iden-
tify correlates of the following: interest in using oral PrEP;
interest in using injectable PrEP; preference for injectable
PrEP compared to other formulations. Bivariate logistic re-
gression models were used to test the association between
PrEP outcomes with disclosure to medical provider, PrEP
awareness, sexual risk behavior, HIV testing behaviors,
and community engagement in sexual health. These vari-
ables were chosen based on previous published literature
in China and factors that have influenced PrEP uptake in
other settings. We examined associations between sexual
risk behaviors and PrEP preferences, adjusting for age,
education, and annual income. Odds ratios (OR) and ad-
justed odds ratios (aOR) were reported with 95% confi-
dence intervals (95%CI) in logistic regression models. An
alpha level of 0.05 or less was considered statistically
significant. All statistical analyses were conducted using
Stata/SE 13.0 (StataCorp, Texas, USA).
Results
Men who did not respond to the PrEP question (n = 66)
were similar to men who responded to this question
(Additional file 1: Table S2). Among the 979 MSM in
this secondary analysis, the median age was 26 (ranged
16–59) (Table 1). They mostly self-identified as gay (768,
78.5%) and most were unmarried (835, 85.3%). More
than three-quarters of the participants had sought a sex-
ual partner online in the last 12 months (745, 76.1%).
About a third of participants (358, 36.6%) had multiple
sexual partners, and around half (499, 51.0%) had con-
domless sex in the last 3 months. Most men had previ-
ously tested for HIV (697/979, 71.2%), but only 42.9%
(299/697) had at least two HIV tests in the last year.
Fewer than half of men (44.9%, n = 426) had a moderate
level of community engagement in sexual health and
31.8% (n = 302) of men had substantial engagement.
Overall, 81.9% (802/979) of the participants had never
heard of PrEP. Following a brief introduction about
PrEP, 85.7% (836/979) of men were interest in using
long-acting injectable PrEP and 76.7% (751/979) of men
were interested in using oral PrEP (Table 2). Among the
751 participants who were interested in using oral PrEP,
93.9% (705/751) also reported interest in using injectable
PrEP. Of the remaining 23.3% (228/979) MSM who were
not interested in using oral PrEP, 57.5% (131/228) were
interested in using injectable PrEP. 90% (882/979) of
men were interested in using at least one formulation of
PrEP. Almost all participants (98.6%, 965/979) com-
pleted the item that asked them to rank PrEP formula-
tions in order of preference. 39.2% (n = 378) of men
ranked rectal microbicides as their most preferred for-
mulation and 36.3% (n = 350) of men ranked injectable
PrEP as preferred. 24.6% (n = 237) of men ranked oral
PrEP as their most preferred formulation. There was no
significant difference in PrEP formulation preference be-
tween participants who who had higher risk sexual be-
haviors (those who had either multiple sexual partners
or had condomless sex in the last 3 months) and the
overall sample.
Table 3 presents the associations between sexual risk
behaviors and interest in PrEP formulations. Adjusting
for the socio-demographic variables (age, education, and
income), men who had ever heard about PrEP (aOR =
1.57, 95%CI 1.02, 2.41), men who had sought sexual
partners online in the last 12 months (aOR = 1.64, 95%CI
1.18, 2.29), men who had multiple male sexual partners
in the last 3 months (aOR = 1.81, 95%CI 1.30, 2.52), and
men who had a higher level of community engagement
in sexual health (aOR =2.67, 95%CI 1.68, 4.27) were
more likely to be interested in oral PrEP. Men who had
sought sexual partners online (aOR = 2.10, 95%CI 1.43,
3.08), men who had multiple sexual partners (aOR =
1.76, 95%CI 1.18, 2.63), men who had multiple HIV tests
in the past year (aOR = 1.94, 95%CI 1.31, 2.88), and men
who had a higher level of community engagement in
sexual health (aOR = 2.25, 95%CI 1.34, 3.79) were more
likely to be interested in injectable PrEP.
Table 4 presents the associations between sexual risk
behaviors and a preference for injectable PrEP using bi-
variate and multivariable logistic regression. We adjusted
for age, education, and income in multivariable logistic
regression. Participants who had ever heard about PrEP
(aOR = 1.55, 95%CI 1.11, 2.17) and who had multiple
HIV tests in the last year (aOR = 1.36, 95%CI 1.04, 1.78)
were more likely to rank injectable PrEP as their most
preferred PrEP formulation. Men who only had recent
receptive anal sex were more likely to prefer injectable
PrEP compared to men who had both recent receptive
and insertive anal sex. (aOR = 0.61, 95%CI 0.43, 0.85).
Discussion
This study contributes to the literature on PrEP accept-
ability by examining preferences for oral and long-acting
injectable PrEP using an online sample of Chinese
MSM. In this study, we found low awareness of PrEP,
but a high interest in using oral and injectable PrEP. We
also found that long-acting PrEP could be an alternative
formulation of PrEP that would be preferred by large
numbers of Chinese MSM. This study expands the lit-
erature on PrEP in China by including a nationwide
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sample of MSM that purposefully over-representing
low-income and closeted MSM who are difficult to
reach using conventional sampling methods.
We found that many MSM in China were unaware of
PrEP. This finding is consistent with earlier studies asses-
sing PrEP awareness rates in China [7, 8, 11, 12]. The
awareness rates we observed in this study are much lower
than rates reported in the US, Canada, and Brazil [24–26].
Low PrEP awareness among MSM in China may have
been related to the lack of an approved drug, lack of Chin-
ese guidelines, lack of support for MSM communities, and
limited drug availability [8, 13]. This finding suggests the
need for further community engagement to increase PrEP
awareness among Chinese MSM.
We found that PrEP interest was associated with re-
ceiving more than one HIV test in a year. MSM who re-
ceived more than one HIV test in a year may either have
more risk behaviors or higher self-perceived risk of ac-
quiring HIV [11, 16, 27]. This finding also suggests that
Table 2 Awareness and preferences for PrEP formulation in
Chinese MSM, 2017 (N = 979)
n % 95%CIc
Ever heard about PrEP
No 802 81.9 79.5, 84.3
Yes 177 18.1 15.7, 20.5
Interested in using oral PrEP
No or not sure 228 23.3 20.7, 26.0
Yes 751 76.7 74.0, 79.3
Interested in using injectable PrEP a
No or not sure 140 14.3 12.3, 16.7
Yes 836 85.7 83.3, 87.7
Preference of PrEP formulations b
Oral PrEP 237 24.6 21.9, 27.4
Injectable PrEP 350 36.3 33.3, 39.4
Rectal Microbicide 378 39.2 36.1, 42.3
a3 missing values
bParticipants were categorized by their first ranked PrEP
formulation preference
cConfidence interval
Table 1 Characteristics of men who have sex with men in
China, 2017 (N = 979)
n (%)
Age (years)
16–24 487 (49.7)
> 24 492 (50.3)
Gender identity
Men 908 (92.8)
Women 24 (2.5)
Transgender 14 (1.4)
Unsure/other 33 (3.4)
Sexual orientation
Gay 768 (78.5)
Bisexual 172 (17.6)
others 39 (4.0)
Educational level
High school or below 425 (43.4)
Above high school 554 (56.6)
Annual income, US$
5500 or below 482 (49.2)
Above 5500 497 (50.8)
Marital status with women
Never married 835 (85.3)
Ever married 144 (14.7)
Disclosed sexual orientation to medical provider
No 520 (53.1)
Yes 459 (46.9)
Partner seeking onlinea
No 234 (23.9)
Yes 745 (76.1)
Multiple male sexual partnersb
No 621 (63.4)
Yes 358 (36.6)
Condomless sexb
No 480 (49.0)
Yes 499 (51.0)
Role during anal sexb
Both 568 (54.4)
Insertive 188 (18.0)
Receptive 240 (23.0)
Multiple HIV testsa,c
No 581 (59.4)
Yes 398 (40.7)
Table 1 Characteristics of men who have sex with men in
China, 2017 (N = 979) (Continued)
n (%)
Community Engagementd
No 121 (12.4)
Minimal 101 (10.3)
Moderate 426 (43.5)
Substantial 302 (30.9)
ain the last 12 months
bin the last 3 months
ctwo or more HIV tests
dN = 950
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PrEP services need to be integrated with HIV testing ser-
vices. Many countries have used HIV testing services as
an entry point for PrEP delivery, adherence monitoring,
and follow-up [3, 28, 29]. The expansion of fourth-
generation HIV testing in many Chinese cities would
help detect early HIV infections and provide an oppor-
tunity for PrEP enrollment.
Our data suggest that many Chinese MSM prefer inject-
able PrEP compared to oral PrEP. This finding is consist-
ent with data from China [16] and the US [30]. The
preference for injectable PrEP may be due to convenience,
decreased frequency of medication taking, and less stigma
[30, 31]. Compared with taking daily oral PrEP, long-
acting injectable PrEP may be more discreet and decrease
the risk of being outed as gay [32]. Injectable PrEP may be
preferred by Chinese MSM who have not yet disclosed
their sexual orientations to others because of the fear of
HIV stigma and homophobia. Furthermore, long-acting
injectable PrEP could simplify adherence monitoring.
Our study has several limitations. First, the PrEP inter-
est was self-reported rather than ascertained by uptake
and most men had not heard of PrEP before this study.
Table 3 Factors and risk behaviors associated with interests in using oral PrEP (N = 979) and injectable PrEP (N = 976) compared to
those are not interested among Chinese MSM, 2017
Oral PrEP Injectable PrEP
OR (95%CIf) aORa (95%CIf) OR (95%CIf) aORa (95%CIf)
Disclosed to medical provider
No Ref Ref Ref Ref
Yes 1.12 (0.83, 1.51) 1.22 (0.90, 1.65) 1.10 (0.77, 1.58) 1.19 (0.83, 1.72)
Ever heard about PrEP
No Ref Ref Ref Ref
Yes 1.61 (1.05, 2.45)* 1.57 (1.02, 2.41)* 1.30 (0.79, 2.13) 1.26 (0.76, 2.08)
Partner seeking onlineb
No Ref Ref Ref Ref
Yes 1.68 (1.21, 2.33)* 1.64 (1.18, 2.29)* 2.12 (1.45, 3.11)* 2.10 (1.43, 3.08)*
Multiple male sexual partnersc
No Ref Ref Ref Ref
Yes 1.69 (1.22, 2.35)* 1.81 (1.30, 2.52)* 1.66 (1.11, 2.47)* 1.76 (1.18, 2.63)*
Condomless sexc
No Ref Ref Ref Ref
Yes 1.21 (0.90, 1.62) 1.23 (0.91, 1.66) 0.98 (0.69, 1.40) 0.99 (0.69, 1.43)
Role during anal sexc
Both Ref Ref Ref Ref
Insertive 0.74 (0.51, 1.08) 0.75 (0.51, 1.10) 0.63 (0.40, 0.98)* 0.64 (0.40, 1.00)
Receptive 0.89 (0.62, 1.27) 0.81 (0.56, 1.17) 0.72 (0.47, 1.10) 0.66 (0.42, 1.02)
Multiple HIV testsb, d
No Ref Ref Ref Ref
Yes 1.39 (1.02, 1.90)* 1.45 (1.06, 1.98)* 1.86 (1.26, 2.76)* 1.94 (1.31, 2.88)*
Community engagement in sexual healthe
No Ref Ref Ref Ref
Minimal 2.28 (1.25, 4.14)* 2.18 (1.19, 3.98)* 3.27 (1.52, 7.05)* 3.16 (1.46, 6.83)*
Moderate 2.21 (1.44, 4.14)* 2.20 (1.42, 3.41)* 2.77 (1.67, 4.57)* 2.77 (1.67, 4.60)*
Substantial 2.56 (1.61, 4.07)* 2.67 (1.68, 4.27)* 2.17 (1.29, 3.63)* 2.25 (1.34, 3.79)*
Logistic regressions use people who were not interested in using oral/injectable PrEP as reference level, do not include people who reported not sure or do not
know whether they were interested in using oral or injectable PrEP. Bold refers to associations that have a 95% CI that does not include 1
aAdjusted variables included age, education, and annual income
bin the last 12 months
cin the last 3 months
dtwo or more HIV tests
eN = 950
fConfidence interval
*p < 0.05
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Although some early studies in China suggested a low
uptake of PrEP among MSM, these pilot studies were
done with minimal community engagement [33, 34].
Our finding of high interest in using PrEP indicates that
a considerable proportion of Chinese MSM may be in-
terested in receiving further information if they have an
introduction. However, considering the complexity of
PrEP usage, future research could focus more messaging
related to PrEP use, side effects, adherence, and financial
support. We also did not ask participants about specific
forms of negotiated safe sexual partnerships which may
influence sexual risk taking and PrEP interest. There
may be unplanned or unspoken safe arrangements be-
tween MSM that influence PrEP interest. Second, the
PrEP formulation preference was based on three options
and associated descriptions provided in the survey. Cau-
tion needs to be taken when generalizing this finding to
MSM who are more familiar with PrEP. At the same
time, this finding may be relevant in many locations
where PrEP is not widely available. Third, the measure
of community engagement in sexual health was focused
on health services. To better measure men’s engagement
with the gay community, qualitative methods or more
community-focused scales would be useful. Fourth, se-
lection bias may have been introduced by the online data
collection approach. However, the quota we assigned
during the recruitment ensured MSM with lower educa-
tion, lower income, and less disclosure. Finally, we did
not explore the participants’ willingness to pay for PrEP.
But given the early stage of adopting PrEP in China,
findings of this study are still valuable in providing evi-
dence for future PrEP trials and formative programs.
Conclusions
Most Chinese MSM were unaware of PrEP but were
willing to use it once they learned about it. Future stud-
ies should consider integrating biomedical prevention
with behavioral intervention and HIV testing services.
Involving MSM communities to promote long-acting in-
jectable formulation of PrEP with oral PrEP may be
more effective than promoting only oral PrEP through
health facilities.
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